Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network).
Mantle cell lymphoma
ibrutinib
prognosis
safety
survival
Journal
American journal of blood research
ISSN: 2160-1992
Titre abrégé: Am J Blood Res
Pays: United States
ID NLM: 101569577
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
06
2021
accepted:
14
07
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Relapsed or refractory (R/R) mantle-cell lymphoma (MCL) patients have a poor prognosis and their management is challenging, in absence of a golden standard as salvage treatment. Bruton's tyrosine kinase inhibitor ibrutinib represents an effective treatment for R/R MCL patients. We investigated ibrutinib efficacy and safety in daily clinical practice, together with factors that could predict disease outcome. We retrospectively analyzed 69 consecutive R/R MCL patients managed in 10 Tuscan onco-hematological centers. The treatment regimen consisted of oral, continuous, single-agent ibrutinib, maximum dosage of 560 mg once per day, until disease progression. Overall response rate was 62.3%, with a CR rate of 39.1%. After a median follow-up of 15.6 months, 40/69 patients (58%) were alive, the main cause of death was progressive disease (PD, 22/69 cases, 31.9%). Median progression-free survival (PFS) and overall survival (OS) were 17 and 34.8 months. Inferior PFS was associated with >1 prior line of therapy and B symptoms. Ibrutinib refractoriness was associated with inferior OS, median OS after ibrutinib failure was only 5 months. In this real-life setting ibrutinib treatment prolonged survival in R/R MCL patients, without unexpected adverse events. Patients receiving ibrutinib as 2
Sections du résumé
BACKGROUND
BACKGROUND
Relapsed or refractory (R/R) mantle-cell lymphoma (MCL) patients have a poor prognosis and their management is challenging, in absence of a golden standard as salvage treatment. Bruton's tyrosine kinase inhibitor ibrutinib represents an effective treatment for R/R MCL patients. We investigated ibrutinib efficacy and safety in daily clinical practice, together with factors that could predict disease outcome.
PATIENTS AND METHODS
METHODS
We retrospectively analyzed 69 consecutive R/R MCL patients managed in 10 Tuscan onco-hematological centers. The treatment regimen consisted of oral, continuous, single-agent ibrutinib, maximum dosage of 560 mg once per day, until disease progression.
RESULTS
RESULTS
Overall response rate was 62.3%, with a CR rate of 39.1%. After a median follow-up of 15.6 months, 40/69 patients (58%) were alive, the main cause of death was progressive disease (PD, 22/69 cases, 31.9%). Median progression-free survival (PFS) and overall survival (OS) were 17 and 34.8 months. Inferior PFS was associated with >1 prior line of therapy and B symptoms. Ibrutinib refractoriness was associated with inferior OS, median OS after ibrutinib failure was only 5 months.
DISCUSSION AND CONCLUSION
CONCLUSIONS
In this real-life setting ibrutinib treatment prolonged survival in R/R MCL patients, without unexpected adverse events. Patients receiving ibrutinib as 2
Types de publication
Journal Article
Langues
eng
Pagination
373-383Informations de copyright
AJBR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Hematol Oncol. 2018 Oct;36(4):624-632
pubmed: 29512173
Lancet. 2016 Feb 20;387(10020):770-8
pubmed: 26673811
Br J Haematol. 2021 Mar;192(6):1035-1038
pubmed: 32445482
Br J Haematol. 2021 Feb;192(4):737-746
pubmed: 33095453
J Clin Oncol. 2009 Aug 10;27(23):3822-9
pubmed: 19581539
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2016 Mar 24;127(12):1559-63
pubmed: 26764355
Target Oncol. 2019 Apr;14(2):125-138
pubmed: 30927175
Leukemia. 2019 Nov;33(11):2762-2766
pubmed: 31558766
Oncotarget. 2018 Mar 27;9(38):25332-25341
pubmed: 29861875
Cancer. 2011 May 1;117(9):1901-10
pubmed: 21509767
Br J Haematol. 2021 Apr;193(2):290-298
pubmed: 33620106
Oncotarget. 2018 May 4;9(34):23443-23450
pubmed: 29805746
Ann Oncol. 2015 Jun;26(6):1175-1179
pubmed: 25712454
Cancer Med. 2019 Nov;8(16):6860-6870
pubmed: 31560165
Br J Haematol. 2020 May;189(4):684-688
pubmed: 32011729
N Engl J Med. 2018 Mar 29;378(13):1211-1223
pubmed: 29590547
Leukemia. 2021 Mar;35(3):787-795
pubmed: 32782382
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
Blood. 2018 Oct 18;132(16):1647-1656
pubmed: 30154113
Blood. 2015 Jan 8;125(2):242-8
pubmed: 25355819
Blood. 2015 Aug 6;126(6):739-45
pubmed: 26059948
Leukemia. 2018 Aug;32(8):1799-1803
pubmed: 29572505
Am J Blood Res. 2020 Dec 15;10(6):355-359
pubmed: 33489445
Br J Haematol. 2017 Nov;179(3):430-438
pubmed: 28832957
Curr Treat Options Oncol. 2019 Nov 27;20(12):85
pubmed: 31776787
Haematologica. 2019 May;104(5):e211-e214
pubmed: 30442728
Lancet Oncol. 2016 Mar;17(3):319-331
pubmed: 26899778
Ann Oncol. 2009 Mar;20(3):520-5
pubmed: 19074748
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71
pubmed: 28881919
Br J Haematol. 2018 Aug;182(3):404-411
pubmed: 29785709
Hematol Oncol. 2017 Dec;35(4):528-535
pubmed: 28066928